Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: translate.bio
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/4/2021 | $45.00 → $38.00 | Neutral | Roth Capital |
| 8/3/2021 | $19.00 → $38.00 | Market Perform | SVB Leerink |
| 8/3/2021 | Outperform → Market Perform | William Blair | |
| 7/26/2021 | $28.00 → $45.00 | Buy | Roth Capital |